Clinical Data Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742 - Multiple ascending doses of VTP-43742 shown to be safe and generally well tolerated in healthy human volunteers - Robust ex vivo biomarker response, suppressing secretion of pro-inflammatory IL-17A by more than 90 percent - Top-line proof-of-concept clinical results from Phase 1 trial of VTP-43742 in psoriatic patients expected in the first quarter of 2016